CreatorsPublishersAdvertisers
View more in
Cancer

Durable Responses Found With Teclistamab in Relapsed or Refractory Multiple Myeloma

cancernetwork.com
 2021-09-06

Cover picture for the articlePatients taking teclistamab for relapsed or refractory multiple myeloma saw durable response, and a well-tolerated toxicity profile. Teclistamab was well tolerated and showed durable responses that depended over time in patients with relapsed or refractory multiple myeloma treated on the phase 1 MajesTec-1 study (NCT03145181), according to a study published in The Lancet.

www.cancernetwork.com

Comments / 1

Comments / 0